Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Apr;66(4):481-5.
doi: 10.1136/ard.2006.059881. Epub 2006 Sep 19.

Sulphasalazine inhibits human antigen-specific immune responses in vivo

Christina Trollmo  1 , Sveinn Gudmundsson, Nils Feltelius, Siv Rogberg, Göran Smedegård, Lars Klareskog
Affiliations
Randomized Controlled Trial

Sulphasalazine inhibits human antigen-specific immune responses in vivo

Christina Trollmo et al. Ann Rheum Dis. 2007 Apr.

Abstract

Objective: To study the effects of the antirheumatic drug sulphasalazine (SASP) on the immune system by analysing systemic and gut-associated immune responses.

Methods: A total of 23 healthy volunteers were treated with either SASP or placebo for 5 weeks in a double-blind fashion and immunised 2 weeks after the initiation of treatment. Specific immune responses were triggered by subcutaneous immunisation with tetanus toxoid and by peroral immunisation with inactivated influenza vaccine. The effects of treatment on specific immunity to tetanus and influenza were evaluated by enzyme-linked immunospot assay quantifying the number of circulating specific and total antibody-producing cells (spot-forming cells (SFC)) at 6, 8 and 10 days after immunisation.

Results: An immunosuppressive effect of SASP on systemic immune response was observed with a decrease in the total number of IgG-SFC, IgG anti-tetanus SFC and IgG anti-tetanus antibody levels in serum. SASP also exerted an immunosuppressive effect on the mucosa-associated immune system as seen from its down-regulating effect on the total number of circulating IgA SFC.

Conclusions: These data show firstly that SASP exerts an immunosuppressive effect on defined immune responses to immunisation in vivo, and secondly that both mucosa-associated and systemic immunity are affected by SASP treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Similar articles

See all similar articles

Cited by

References

    1. Cannella A C, O'Dell J R. Is there still a role for traditional disease‐modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Curr Opin Rheumatol 200315185 - PubMed
    1. Scott D L, Smolen J S, Kalden J R, van de Putte L B, Larsen A, Kvien T K.et al Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 200160913 - PMC - PubMed
    1. O'Dell J R, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff P J.et al Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2002461164 - PubMed
    1. Haagsma C J, van Riel P L, de Jong A J, van de Putte L B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double‐blind, 52 week clinical trial. Br J Rheumatol 1997361082 - PubMed
    1. Aletaha D T, Stamm T, Kapral G, Eberl J, Grisar K, Machold P.et al Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 200362944 - PMC - PubMed

Publication types

MeSH terms